Literature DB >> 8397233

Changes in myocardial and vascular receptors in heart failure.

M R Bristow1.   

Abstract

Heart failure results in dramatic changes in certain neurotransmitter and hormone receptors. The majority of the changes occur in the heart and generally can be classified as regulatory phenomena that withdraw the failing heart from adrenergic stimulation. Of these, the most prominent is beta 1-receptor downregulation. Changes in vascular receptors are much less prominent and there is no direct evidence that any vascular receptor changes in heart failure. The changes that occur in myocardial receptors suggest that antiadrenergic therapy would be effective in the treatment of heart failure by removing adrenergic signaling transduced by the remaining components of the receptor pathways. Taken together, the receptor desensitization changes present in the failing heart provide a rationale for beta 1- plus beta 2-adrenergic blockade or even combined beta 1-, beta 2-alpha 1-adrenergic receptor blockade in heart failure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397233     DOI: 10.1016/0735-1097(93)90465-d

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

Review 1.  Functional M3 muscarinic acetylcholine receptors in mammalian hearts.

Authors:  Zhiguo Wang; Hong Shi; Huizhen Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 2.  The role of the autonomic nervous system in sudden cardiac death.

Authors:  Marmar Vaseghi; Kalyanam Shivkumar
Journal:  Prog Cardiovasc Dis       Date:  2008 May-Jun       Impact factor: 8.194

Review 3.  Cardioprotection: definition, classification, and fundamental principles.

Authors:  W Kübler; M Haass
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

4.  Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors.

Authors:  E A Dubois; G A Somsen; J C van den Bos; A G Janssen; G J Boer; H D Batink; E A van Royen; M Pfaffendorf; P A van Zwieten
Journal:  J Nucl Cardiol       Date:  1996 May-Jun       Impact factor: 5.952

Review 5.  The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions.

Authors:  J Chris Baldi; Genevieve A Wilson; Luke C Wilson; Gerard T Wilkins; Regis R Lamberts
Journal:  Sports Med       Date:  2016-11       Impact factor: 11.136

6.  Boosting the reserves: additive regulation of cardiac repolarisation.

Authors:  Adam P Hill
Journal:  J Physiol       Date:  2017-02-21       Impact factor: 5.182

Review 7.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

8.  Sympathetic stimulation increases dispersion of repolarization in humans with myocardial infarction.

Authors:  Marmar Vaseghi; Robert L Lux; Aman Mahajan; Kalyanam Shivkumar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-17       Impact factor: 4.733

Review 9.  Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.

Authors:  Abhishek Jaiswal; Vinh Q Nguyen; Thierry H Le Jemtel; Keith C Ferdinand
Journal:  World J Cardiol       Date:  2016-07-26

10.  Clinical and genetic modifiers of long-term survival in heart failure.

Authors:  Sharon Cresci; Reagan J Kelly; Thomas P Cappola; Abhinav Diwan; Daniel Dries; Sharon L R Kardia; Gerald W Dorn
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.